EmailHospital Circular 21/2006
Date Issued: 4 December 2006
Distribution: Public Health Services, Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 December 2006
We have had recent advice from the Commonwealth Government of a change to the Highly Specialised Drugs Program, effective 1 December 2006.
ADDED DRUGS
Deferasirox |
|||||
| 6499C | Tablet 125mg (dispersible) | 28 | $186.87 | Exjade | NV |
| 6500D | Tablet 250mg (dispersible) |
28 | $373.73 | Exjade | NV |
| 9600G | Tablet 500mg (dispersible) |
28 | $747.46 | Exjade | NV |
Entecavir monohydrate |
|||||
| 9602J | Tablet 0.5mg | 30 | $384.30 | Baraclude | BQ |
| 9603K | Tablet 1mg | 30 | $625.00 | Baraclude | BQ |
ADDED FORMS
Saquinavir mesylate |
|||||
| 6498B | Tablet 500mg (base) | 120 | $505.56 | Invirase | RO |
Pegfilgrastim |
|||||
| 9601H | Injection 6mg in 0.6ml pre-filled injection (single use) | 1 | $1925.00 | Neulasta SureClick |
AN |
PRICE INCREASES
Octreotide acetate |
|||||
| 6227R | Injection 50mcgms in 1ml | 5 | $41.76 | Sandostatin 0.05 | NV |
| 6228T | Injection 100mcgms in 1ml | 5 | $83.50 | Sandostatin 0.1 | NV |
| 6229W | Injection 500mcgms in 1ml | 5 | $417.96 | Sandostatin 0.5 | NV |
Cyclosporin |
|||||
| 6352H | Capsule 25mg | 30 | $41.63 | Cicloral Neoral 25 |
HX NV |
| 6353J | Capsule 50mg | 30 | $86.60 | Cicloral Neoral 50 |
HX NV |
| 6354K | Capsule 100mg | 30 | $176.45 | Cicloral Neoral 100 |
HX NV |
Interferon Gamma 1b |
|||||
| 6148N | Injection 2,000,000 i.u. in 0.5ml | 6 | $1,260.09 | Imukin | BY |
Deferiprone |
|||||
| 6416Q | Tablet 500mg | 100 | $440.00 | Ferriprox | OA |
Sirolimus |
|||||
| 6436R | Tablet 1mg | 100 | $723.33 | Rapamune | WY |
| 6437T | Oral solution 1mg per 60ml | 1 | $434.00 | Rapamune | WY |
| 6457W | Tablet 2mg | 100 | $1,446.67 | Rapamune | WY |
AMENDED RESTRICTION
Infliximab |
|||||
| 6448J | Powder for IV infusion 100mg | 1 | $875.00 | Remicade | SH |
The restriction for infliximab for ankylosing spondylitits has been amended by removing the references to the HLA B27 requirement.
PRICE DECREASES
Clarithromycin |
|||||
| 6151R | Tablet 250mg | 100 | $48.16 | Klacid | AB |
| 6152T | Tablet 500mg | 100 | $96.32 | Klacid | AB |
DELETED FORMS
Ritonavir |
||||
| 6235E | Oral solution 600mg per 7.5ml 240ml | 1 | Norvir | AB |
Efavirenz |
||||
| 6259K | Capsule 100mg | 30 | Stocrin | MK |
DELETED BRANDS
Octreotide acetate |
|||
| 6227R | Injection 50mcgm in 1ml | 5 | MX |
| 6228T | Injection 100mcgm in 1ml | 5 | MX |
| 6229W | Injection 500mcgms in 1ml | 5 | MX |
Cyclosporin |
||||
| 6352H | Capsule 25mg | 30 | Cysporin | MX |
| 6353J | Capsule 50mg | 30 | Cysporin | MX |
| 6354K | Capsule 100mg | 30 | Cysporin | MX |
OTHER AMENDMENTS
Disodium pamidronate
Additional note added: “The concentrated injection and powder for
I.V. infusion (after reconstitution) are bioequivalent.”
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Lea Pope
Acting Director, Programs
Metropolitan Health & Aged Care Services
